Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
$KONEF is pleased to announce it has signed an exclusive agreement for the use of virtual reality (“VR”) technology in psychedelic treatments with OVR Tech LLC (“OVR Technology”) to provide its INHALE Wellness Platform over an initial term of two years in Ketamine One’s clinics. https://finance.yahoo.com/news/ketamine-one-scent-enabled-virtual-110000242.html
Ketamine One to Provide Scent-Enabled Virtual Reality Via Exclusive Agreement for Psychedelic Molecules With OVR Technology
Agreement Provides Ketamine One With First-of-its-Kind VR Scent Capabilities to Generate More Realistic Immersive Experiences and Help Improve Patient Treatment Outcomes
VANCOUVER, British Columbia, Aug. 04, 2021 (GLOBE NEWSWIRE) -- KetamineOne Capital Limited (“Ketamine One” or the “Company”) (NEO: MEDI) (OTC: KONEF) (Frankfurt: MY0), a company focused on consolidating medical clinics and becoming a North American leader in mental health treatments, is pleased to announce it has signed an exclusive agreement for the use of virtual reality (“VR”) technology in psychedelic treatments with OVR Tech LLC (“OVR Technology”) to provide its INHALE Wellness Platform over an initial term of two years in Ketamine One’s clinics. The INHALE Wellness Platform is an olfactory-enabled VR platform designed to deepen immersion, promote relaxation and help manage stress.
Pursuant to the terms and conditions of the exclusive agreement, OVR Technology will provide its proprietary technology and services for Ketamine One to use with its psychedelic-assisted treatments involving ketamine, psilocybin, DMT and MDMA in order to help improve patient outcomes. OVR Technology’s INHALE Wellness Platform combines the benefits of mindfulness, breathwork and meditation with the next generation of aromatherapy. It includes a head-mounted display, the ION device (the “ION”) and scent cartridges, as well as several scent-focused nature scenes. The ION is lightweight, wireless and emits scent particles in coordination with VR technology designed to deepen a patient’s immersive experience.
The Architecture of Scent® platform and ION Device
OVR Technology’s Architecture of Scent® platform brings together software, Scentware™, and hardware via the ION, while also including replaceable cartridges and an Olfactory Experience Engine that allows scent to be triggered during a VR experience. Scents delivered through the ION are water-based and made from a combination of natural and synthetic ingredients that have undergone extensive testing. While VR technology is widely known to incorporate sight and sound, this partnership provides Ketamine One with the capability to generate more realistic Immersive Virtual Reality (“IVR”) service offerings via scent at its network of clinics, which is expected to enhance experiences and help improve patient treatment outcomes.
The concept for the Architecture of Scent® and ION device was based on the idea that scent in VR could dramatically increase immersion. Computer simulations in which patients can interact within virtual three-dimensional environments can help put patients in calming settings and improve relaxation through the addition of scents. Research has shown that scents elicit emotional and evocative associations and can immediately alter mood.1 Other research shows that, as soon as an odor is registered by the brain, it activates the amygdala-hippocampal complex in the limbic system where emotions, memories, and associations are processed, nearly instantaneously.2
Management Commentary
“We believe that the ION device contains the most accurate on-mask scent technology currently available on the market. The ability for our clinicians to alter perceptual experiences with VR and the ION is extremely promising. Optimizing the therapeutic setting is one of the main goals of our VR-based research and development program and being able to utilize the sense of smell to help patients relax, reduce tension and lower stress is expected to result in the development of a comprehensive treatment,” said Dr. Quang Henderson, Chair of Ketamine One’s Clinic Innovation Council.
“Our access to a large patient population and enhanced research capabilities through our wholly-owned contract research organization, KGK Science, along with OVR Technology’s innovative platform, on a combined basis have the potential to lead to clinically validated solutions for use not only in our facilities, but also in patients’ homes, through the development of a portable digital therapeutic offering in the future,” added Adam Deffett, Interim CEO of Ketamine One.
“This is the first VR platform that understands user behavior in the virtual world and responds with real-time sensory stimulation. It has the potential to significantly enhance the wellness capabilities of an already promising technology,” said Aaron Wisniewski, CEO and co-founder of OVR Technology.
ABOUT OVR TECHNOLOGY
Founded in 2017, OVR Technology is based in Burlington, Vermont and is a leader in providing scent solutions for virtual reality, augmented reality and other digital environments. OVR Technology combines people’s most primal sense, which is smell, with today’s most advanced technology, to unlock the potential of virtual reality. Better virtual reality, better reality. Learn more at https://ovrtechnology.com.
ABOUT KETAMINE ONE
KetamineOne Capital Limited (formerly Myconic Capital Corp.) is a company focused on consolidating medical clinics and becoming a North American leader in mental health treatments. It is working to provide the critical infrastructure needed to develop and deliver breakthrough mental health treatments. Currently, Ketamine One has a network of 16 clinics across North America, with plans to further consolidate the highly fragmented industry. The recent addition of KGK Science Inc. as the Company’s contract research division also places the company at the forefront of premium clinical research based on its 23-year history and extensive experience in pharmaceuticals, cannabis, and the emerging psychedelic medicine industries. As a collective enterprise, Ketamine One is dedicated to helping solve the growing need for safe and accessible mental health therapy.
On behalf of:
KETAMINE ONE
"Adam Deffett"
Adam Deffett, Interim CEO
For further information, please contact:
Nick Kuzyk, Investor Relations
Tel: 1-844-PHONE-K1 (1-844-746-6351)
Email: IR@ketamine.one
Web: http://www.ketamine.one
Twitter: @KetamineOne
Notice Regarding Forward-Looking Information:
This news release contains forward-looking statements including but not limited to statements regarding the Company’s business, assets or investments, as well other statements that are not historical facts. Readers are cautioned not to place undue reliance on forward-looking statements, as there can be no assurance that the plans, intentions or expectations upon which they are based will occur. By their nature, forward-looking statements involve numerous assumptions, known and unknown risks and uncertainties, both general and specific, that contribute to the possibility that the predictions, forecasts, projections and other forward-looking statements will not occur, which may cause actual performance and results in future periods to differ materially from any estimates or projections of future performance or results expressed or implied by such forward-looking statements. These assumptions, risks and uncertainties include, among other things, the state of the economy in general and capital markets in particular, investor interest in the business and future prospects of the Company.
The forward-looking statements contained in this news release are made as of the date of this news release. Except as required by law, the Company disclaims any intention and assumes no obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by applicable securities law. Additionally, the Company undertakes no obligation to comment on the expectations of, or statements made, by third parties in respect of the matters discussed above.
Notes:
Herz, 1998; 2009; Herz et al., 2004; Larsson et al., 2014.
Herz, 2020.
Source: KetamineOne Capital Limited
$KONEF NEWS! Ketamine One to Provide Scent-Enabled Virtual Reality Via Exclusive Agreement for Psychedelic Molecules With OVR Technology https://lnkd.in/gpyyCadU
Smallcap stock KetamineOne ( OTC: $KONEF, NEO: $MEDI ) is consolidating the North American clinic industry providing breakthrough therapies. #StocksToWatch
Smallcap stock KetamineOne ( OTC: $KONEF, NEO: $MEDI ) is consolidating the North American clinic industry providing breakthrough therapies. #StocksToWatch
— The Next Hot Stock (@HotstocksReview) August 3, 2021
My brain on ketamine: In a struggle with depression, a new drug gives me hope, and more questions.https://t.co/sRs7joBETJ
$KONEF The Company and Its Subsidiary KGK Science Have Also Completed the Pre-Qualification Audits of Its Canadian Facilities to Enable Clinical Trials in an Arrangement with Aleafia Health https://finance.yahoo.com/news/ketamine-one-advances-research-capabilities-110000639.html
$KONEF has acquired 16 clinics across North America, with LOI’s signed for additional clinics. Its team is in the process of building the infrastructure needed to provide ketamine treatments through existing clinics, experienced professionals, and tech.
Ketamine One has made some really smart moves in a very short period of time. They essentially bought a turnkey business from Canabo, and have it set up that Canabo’s expertise won’t be wasted or forgotten moving forward. Their foray into tech reminds me of Cybin (CYBN.NE) approach with their partnership with Kernel. Ketamine One is headed in the right direction in terms of early stage revenue and profitability, and their other M&A activity shows that they are willing to think outside the box and not be just another generic psychedelics company.
$KONEF ~ From cannabis clinics to ketamine clinics, how Ketamine One Capital (MEDI.NE) is rapidly scaling its business https://equity.guru/2021/07/ketamine-one-capital-medi-ne-is-converting-cannabis-clinics-into-ketamine-clinics/
NeuroCatch is expected to remain a key part of IRP’s service offering as Ketamine One expands its network to new veteran-centric markets across Canada. Unique service offerings such as NeuroCatch help Ketamine One’s clinicians create more tailored treatment plans for patients, which can increase their effectiveness over time. Platforms like NeuroCatch are also significant as Ketamine One embarks on embracing digital therapeutics as a core element of its competitive strategy. Psychedelics-focused research, a growing network of medical clinics, a broad suite of patient treatment options and leading technologies including digital therapeutics are all being brought together to create a unique mental health platform under Ketamine One. $KONEF
$KONEF Share Structure, even the O/S is very reasonable?
Outstanding Shares
119,014,018 07/28/2021
Restricted
15,824,383 07/28/2021
Unrestricted
103,189,635 07/28/2021
Float
40,983,026 07/14/2021
$KONEF and KGK...looks like a great future for both companies.
“Today’s announcements are further evidence of the synergies between our growing clinic network and our contract research offerings,” said Ketamine One’s Interim CEO, Adam Deffett. “KGK will now have the ability to utilize our clinic sites for future trials, gain access to a large patient database and, upon approval, have a narcotic dealers license. Our goal is that these initiatives will also provide Ketamine One patients with breakthrough treatments through clinical trials and our clinical staff with experience and protocols needed for the eventual expansion of new treatments. We view this as a great opportunity to demonstrate their operational capabilities while also earning a new revenue stream from Ketamine One,” added Mr. Deffett.
This is HUGE news for $KONEF, looking forward to seeing approval soon.
Subject to the approval of Health Canada, the licence will effectively enable KGK to offer a turn-key solution for third parties to conduct clinical trials involving psychedelic molecules, while also authorizing KGK to act as a centralized distributor for large, multi-location clinical trials.
News: Full PR: Ketamine One Advances Research Capabilities via Controlled Substance Dealers Licence Application
KetamineOne Capital Limited
Wed, July 28, 2021, 7:00 AM
The Company and Its Subsidiary KGK Science Have Also Completed the Pre-Qualification Audits of Its Canadian Facilities to Enable Clinical Trials in an Arrangement with Aleafia Health
VANCOUVER, British Columbia, July 28, 2021 (GLOBE NEWSWIRE) -- KetamineOne Capital Limited (“Ketamine One” or the “Company”) (NEO: MEDI) (OTC: KONEF) (Frankfurt: MY0), a company focused on consolidating medical clinics and becoming a North American leader in mental health treatments, is pleased to announce that its wholly-owned contract research organization (“CRO”), KGK Science Inc., (“KGK”) has recently achieved several milestones in its psychedelic research capabilities and significantly expanded its access to patients through further integration with Ketamine One.
Controlled Drugs and Substances Dealer’s Licence:
KGK recently applied for a controlled drugs and substances dealer’s licence under Canada’s Narcotic Control Regulations governing the possession, distribution, sale, clinical studies of and research and development of controlled substances, including Psilocybin, Psilocin, Ketamine, MDMA, LSD, DMT, Mescaline, Salvinorin A, Harmaline and Harmalol. Subject to the approval of Health Canada, the licence will effectively enable KGK to offer a turn-key solution for third parties to conduct clinical trials involving psychedelic molecules, while also authorizing KGK to act as a centralized distributor for large, multi-location clinical trials.
Pre-Qualification of Canadian Facilities for Clinical Trials:
Additionally, Ketamine One has completed the pre-qualification audits of its Canadian clinics with KGK to prepare for the use of the Company’s facilities in future clinical trials. The audits will enable KGK to conduct clinical trials in the areas of psychedelics and nutraceuticals, among other substances of study. This direct access to patients and clinics is expected to differentiate KGK from other CROs by providing the opportunity to study patients with differing demographics across various populations, while also shortening recruitment timelines for studies.
The Company has been focused on a swift integration of the medical clinics that Ketamine One previously announced on May 7th as having been acquired from Canabo Medical Corporation, a wholly-owned subsidiary of Aleafia Health Inc. (TSX: AH) (“Aleafia”) together with its other recent acquisition of KGK announced on June 3rd.
Additionally, as previously announced on January 21, 2021, Unifor and Aleafia entered into an exclusive 10-year agreement to support union members, retirees and their eligible dependents that receive medical cannabis insurance coverage clinics through Unifor's collective bargaining agreements. To date, the clinic network has seen over 75,000 unique patients and has conducted extensive research in cannabinoid therapy as it relates to sleeping disorders, opioid reduction and other topics.
Management Commentary:
“Today’s announcements are further evidence of the synergies between our growing clinic network and our contract research offerings,” said Ketamine One’s Interim CEO, Adam Deffett. “KGK will now have the ability to utilize our clinic sites for future trials, gain access to a large patient database and, upon approval, have a narcotic dealers license. Our goal is that these initiatives will also provide Ketamine One patients with breakthrough treatments through clinical trials and our clinical staff with experience and protocols needed for the eventual expansion of new treatments. We view this as a great opportunity to demonstrate their operational capabilities while also earning a new revenue stream from Ketamine One,” added Mr. Deffett.
General Research:
The Company has engaged General Research GmbH (“GR”) to increase its exposure to investors in Europe. The services agreement with GR has an aggregate cash cost of 40,000 Euros, has an initial term of two months, and such term may be extended for subsequent periods. GR will not receive any securities of the Company as compensation, and it does not currently own any securities of Ketamine One. Ketamine One and GR are unrelated and unaffiliated entities; GR is arm’s length to the Company.
ABOUT KETAMINE ONE
KetamineOne Capital Limited (formerly Myconic Capital Corp.) is a company focused on consolidating medical clinics and becoming a North American leader in mental health treatments. It is working to provide the critical infrastructure needed to develop and deliver breakthrough mental health treatments. Currently, Ketamine One has a network of 16 clinics across North America, with plans to further consolidate the highly fragmented industry. The recent addition of KGK Science Inc. as the Company’s contract research division also places the company at the forefront of premium clinical research based on its 23-year history and extensive experience in pharmaceuticals, cannabis, and the emerging psychedelic medicine industries. As a collective enterprise, Ketamine One is dedicated to helping solve the growing need for safe and accessible mental health therapy.
On behalf of:
KETAMINE ONE
"Adam Deffett"
Adam Deffett, Interim CEO
For further information, please contact:
Nick Kuzyk, Investor Relations
Tel: 1-844-PHONE-K1 (1-844-746-6351)
Email: IR@ketamine.one
Web: www.ketamine.one
Twitter: @KetamineOne
Notice Regarding Forward-Looking Information:
This news release contains forward-looking statements including but not limited to statements regarding the Company’s business, assets or investments, as well other statements that are not historical facts. Readers are cautioned not to place undue reliance on forward-looking statements, as there can be no assurance that the plans, intentions or expectations upon which they are based will occur. By their nature, forward-looking statements involve numerous assumptions, known and unknown risks and uncertainties, both general and specific, that contribute to the possibility that the predictions, forecasts, projections and other forward-looking statements will not occur, which may cause actual performance and results in future periods to differ materially from any estimates or projections of future performance or results expressed or implied by such forward-looking statements. These assumptions, risks and uncertainties include, among other things, the state of the economy in general and capital markets in particular, investor interest in the business and future prospects of the Company.
The forward-looking statements contained in this news release are made as of the date of this news release. Except as required by law, the Company disclaims any intention and assumes no obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by applicable securities law. Additionally, the Company undertakes no obligation to comment on the expectations of, or statements made, by third parties in respect of the matters discussed above.
News Out! July 28, 2021 (GLOBE NEWSWIRE) -- KetamineOne Capital Limited (“Ketamine One” or the “Company”) (NEO: MEDI) (OTC: KONEF) (Frankfurt: MY0), a company focused on consolidating medical clinics and becoming a North American leader in mental health treatments, is pleased to announce that its wholly-owned contract research organization (“CRO”), KGK Science Inc., (“KGK”) has recently achieved several milestones in its psychedelic research capabilities and significantly expanded its access to patients through further integration with Ketamine One.
Controlled Drugs and Substances Dealer’s Licence:
KGK recently applied for a controlled drugs and substances dealer’s licence under Canada’s Narcotic Control Regulations governing the possession, distribution, sale, clinical studies of and research and development of controlled substances, including Psilocybin, Psilocin, Ketamine, MDMA, LSD, DMT, Mescaline, Salvinorin A, Harmaline and Harmalol. Subject to the approval of Health Canada, the licence will effectively enable KGK to offer a turn-key solution for third parties to conduct clinical trials involving psychedelic molecules, while also authorizing KGK to act as a centralized distributor for large, multi-location clinical trials.
$KONEF is moving ahead whilst looking for a new CEO...
Our team is working hard to establish Ketamine One as the preeminent mental health platform for patients, by aggregating existing medical clinics and establishing new locations, while supporting KGK Science as a leading clinical research organization and implementing leading technologies throughout the organization wherever possible,” added Mr. Deffett.
$KONEF Ketamine One Announces Adam Deffett as Interim CEO https://finance.yahoo.com/news/ketamine-one-announces-adam-deffett-110000763.html?soc_src=social-sh&soc_trk=tw&tsrc=twtr via @Yahoo
In 2019, Health Canada approved the NeuroCatch Platform a class II medical device developed by HealthTech Connex Inc. that conducts a rapid 6-minute scan to measure and report on cognitive brain function. It is an easy-to-use, objective, rapid neuro-physiological brain function assessment system, that provides healthcare practitioners with objective measurements of specific brain functions: auditory sensation; basic attention and cognitive processing. Researchers and clinicians use this technology to gain insight into a range of common neurological conditions, including concussion and brain injury; dementia and neurological disease; post-traumatic stress disorder and mental health; and brain performance and human optimization.
KONEF
Looking forward to hearing more about $KONEF expansion...
NeuroCatch is expected to remain a key part of IRP’s service offering as Ketamine One expands its network to new veteran-centric markets across Canada. Unique service offerings such as NeuroCatch help Ketamine One’s clinicians create more tailored treatment plans for patients, which can increase their effectiveness over time. Platforms like NeuroCatch are also significant as Ketamine One embarks on embracing digital therapeutics as a core element of its competitive strategy. Psychedelics-focused research, a growing network of medical clinics, a broad suite of patient treatment options and leading technologies including digital therapeutics are all being brought together to create a unique mental health platform under Ketamine One.
$KONEF Ketamine One’s IRP Clinic Using Innovative NeuroCatch Platform to Measure Brain Function in Injured Veterans https://finance.yahoo.com/news/ketamine-one-irp-clinic-using-110000073.html?soc_src=social-sh&soc_trk=tw&tsrc=twtr via @Yahoo
Interesting information on the $KONEF NeuroCatch...
It is an easy-to-use, objective, rapid neuro-physiological brain function assessment system, that provides healthcare practitioners with objective measurements of specific brain functions: auditory sensation; basic attention and cognitive processing. Researchers and clinicians use this technology to gain insight into a range of common neurological conditions, including concussion and brain injury; dementia and neurological disease; post-traumatic stress disorder and mental health; and brain performance and human optimization.
$KONEF UPDATE; The NeuroCatch Platform is a 6-Minute Brain Function Assessment System Licensed by Health Canada as a Class II Medical Device;Ketamine One’s IRP Clinic Using Innovative NeuroCatch Platform to Measure Brain Function in Injured Veterans https://finance.yahoo.com/news/ketamine-one-irp-clinic-using-110000073.html?soc_src=social-sh&soc_trk=tw&tsrc=twtr @Yahoo
The NeuroCatch Platform is a 6-Minute Brain Function Assessment System Licensed by Health Canada as a Class II Medical Device
VANCOUVER, British Columbia, July 22, 2021 (GLOBE NEWSWIRE) -- KetamineOne Capital Limited (“Ketamine One” or the “Company”) (NEO: MEDI) (OTC: KONEF) (Frankfurt: MY0), a company focused on consolidating medical clinics and becoming a North American leader in mental health treatments, is pleased to highlight the continued success of the Health Canada-approved NeuroCatch Platform (“NeuroCatch”) in use at its Integrated Rehab and Performance Ltd. (“IRP”) clinic in Victoria, BC. IRP has been an early adopter of NeuroCatch’s advanced brain-scanning technology to better understand brain health and neurocognitive function in patients since September of 2020. NeuroCatch continues to differentiate IRP from other rehabilitation clinics, along with its unique focus on patients from the Canadian Armed Forces, the Royal Canadian Mounted Police and various first responder organizations.
NeuroCatch is expected to remain a key part of IRP’s service offering as Ketamine One expands its network to new veteran-centric markets across Canada. Unique service offerings such as NeuroCatch help Ketamine One’s clinicians create more tailored treatment plans for patients, which can increase their effectiveness over time. Platforms like NeuroCatch are also significant as Ketamine One embarks on embracing digital therapeutics as a core element of its competitive strategy. Psychedelics-focused research, a growing network of medical clinics, a broad suite of patient treatment options and leading technologies including digital therapeutics are all being brought together to create a unique mental health platform under Ketamine One.
NeuroCatch:
In 2019, Health Canada approved the NeuroCatch Platform a class II medical device developed by HealthTech Connex Inc. that conducts a rapid 6-minute scan to measure and report on cognitive brain function. It is an easy-to-use, objective, rapid neuro-physiological brain function assessment system, that provides healthcare practitioners with objective measurements of specific brain functions: auditory sensation; basic attention and cognitive processing. Researchers and clinicians use this technology to gain insight into a range of common neurological conditions, including concussion and brain injury; dementia and neurological disease; post-traumatic stress disorder and mental health; and brain performance and human optimization.
Aside from its relationship with IRP, NeuroCatch is currently also collaborating or partnered with a long list of third parties including but not limited to Alberta Children’s Hospital, CAA Hockey, Canadian Space Agency, Equinox Integrative Wellness, Helius Medical Technologies, Kids Brain Health Network, Mayo Clinic, Toronto Rehabilitation Institute, University Health Network, University of Alberta, University of Calgary, University of Toronto, University of Victoria and Weill Cornell Medicine.
$KONEF trading well on today's News...
Great $KONEF PR today...
NeuroCatch is expected to remain a key part of IRP’s service offering as Ketamine One expands its network to new veteran-centric markets across Canada. Unique service offerings such as NeuroCatch help Ketamine One’s clinicians create more tailored treatment plans for patients, which can increase their effectiveness over time. Platforms like NeuroCatch are also significant as Ketamine One embarks on embracing digital therapeutics as a core element of its competitive strategy. Psychedelics-focused research, a growing network of medical clinics, a broad suite of patient treatment options and leading technologies including digital therapeutics are all being brought together to create a unique mental health platform under Ketamine One.
Huge news there!
KONEF
$KONEF News! Ketamine One’s IRP Clinic Using Innovative NeuroCatch Platform to Measure Brain Function in Injured Veterans https://finance.yahoo.com/news/ketamine-one-irp-clinic-using-110000073.html?soc_src=social-sh&soc_trk=tw&tsrc=twtr
NeuroCatch is expected to remain a key part of IRP’s service offering as Ketamine One expands its network to new veteran-centric markets across Canada. Unique service offerings such as NeuroCatch help Ketamine One’s clinicians create more tailored treatment plans for patients, which can increase their effectiveness over time. Platforms like NeuroCatch are also significant as Ketamine One embarks on embracing digital therapeutics as a core element of its competitive strategy. Psychedelics-focused research, a growing network of medical clinics, a broad suite of patient treatment options and leading technologies including digital therapeutics are all being brought together to create a unique mental health platform under Ketamine One. $KONEF
News: Ketamine One’s IRP Clinic Using Innovative NeuroCatch Platform to Measure Brain Function in Injured Veterans
KetamineOne Capital Limited
Thu, July 22, 2021, 7:00 AM
The NeuroCatch Platform is a 6-Minute Brain Function Assessment System Licensed by Health Canada as a Class II Medical Device
VANCOUVER, British Columbia, July 22, 2021 (GLOBE NEWSWIRE) -- KetamineOne Capital Limited (“Ketamine One” or the “Company”) (NEO: MEDI) (OTC: KONEF) (Frankfurt: MY0), a company focused on consolidating medical clinics and becoming a North American leader in mental health treatments, is pleased to highlight the continued success of the Health Canada-approved NeuroCatch Platform (“NeuroCatch”) in use at its Integrated Rehab and Performance Ltd. (“IRP”) clinic in Victoria, BC. IRP has been an early adopter of NeuroCatch’s advanced brain-scanning technology to better understand brain health and neurocognitive function in patients since September of 2020. NeuroCatch continues to differentiate IRP from other rehabilitation clinics, along with its unique focus on patients from the Canadian Armed Forces, the Royal Canadian Mounted Police and various first responder organizations.
NeuroCatch is expected to remain a key part of IRP’s service offering as Ketamine One expands its network to new veteran-centric markets across Canada. Unique service offerings such as NeuroCatch help Ketamine One’s clinicians create more tailored treatment plans for patients, which can increase their effectiveness over time. Platforms like NeuroCatch are also significant as Ketamine One embarks on embracing digital therapeutics as a core element of its competitive strategy. Psychedelics-focused research, a growing network of medical clinics, a broad suite of patient treatment options and leading technologies including digital therapeutics are all being brought together to create a unique mental health platform under Ketamine One.
NeuroCatch:
In 2019, Health Canada approved the NeuroCatch Platform a class II medical device developed by HealthTech Connex Inc. that conducts a rapid 6-minute scan to measure and report on cognitive brain function. It is an easy-to-use, objective, rapid neuro-physiological brain function assessment system, that provides healthcare practitioners with objective measurements of specific brain functions: auditory sensation; basic attention and cognitive processing. Researchers and clinicians use this technology to gain insight into a range of common neurological conditions, including concussion and brain injury; dementia and neurological disease; post-traumatic stress disorder and mental health; and brain performance and human optimization.
Aside from its relationship with IRP, NeuroCatch is currently also collaborating or partnered with a long list of third parties including but not limited to Alberta Children’s Hospital, CAA Hockey, Canadian Space Agency, Equinox Integrative Wellness, Helius Medical Technologies, Kids Brain Health Network, Mayo Clinic, Toronto Rehabilitation Institute, University Health Network, University of Alberta, University of Calgary, University of Toronto, University of Victoria and Weill Cornell Medicine.
For more information about NeuroCatch, please visit www.neurocatch.com.
Management Commentary:
“Embracing technology is essential for improving our patients’ outcomes at IRP and giving them the best care throughout their healing and recovery processes. The use of NeuroCatch enables our staff to customize treatment plans and track improvements in brain health of our patients,” said Steven Inglefield, Founder & CEO of IRP. “Ketamine One’s continued integration of industry-leading clinics and the most advanced treatment options gives clinicians greater insights into every patient’s care, while the Company’s research assets provide the ability to stay at the forefront of breakthrough treatments and technologies,” added Mr. Inglefield.
ABOUT KETAMINE ONE
KetamineOne Capital Limited (formerly Myconic Capital Corp.) is a company focused on consolidating medical clinics and becoming a North American leader in mental health treatments. It is working to provide the critical infrastructure needed to develop and deliver breakthrough mental health treatments. Currently, Ketamine One has a network of 16 clinics across North America, with plans to further consolidate the highly fragmented industry. The recent addition of KGK Science Inc. as the Company’s contract research division also places the company at the forefront of premium clinical research based on its 23-year history and extensive experience in pharmaceuticals, cannabis, and the emerging psychedelic medicine industries. As a collective enterprise, Ketamine One is dedicated to helping solve the growing need for safe and accessible mental health therapy.
On behalf of:
KETAMINE ONE
"Adam Deffett"
Adam Deffett, Interim CEO
For further information, please contact:
Nick Kuzyk, Investor Relations
Tel: 1-844-PHONE-K1 (1-844-746-6351)
Email: IR@ketamine.one
Web: www.ketamine.one
Twitter: @KetamineOne
Notice Regarding Forward-Looking Information:
This news release contains forward-looking statements including but not limited to statements regarding the Company’s business, assets or investments, as well other statements that are not historical facts. Readers are cautioned not to place undue reliance on forward-looking statements, as there can be no assurance that the plans, intentions or expectations upon which they are based will occur. By their nature, forward-looking statements involve numerous assumptions, known and unknown risks and uncertainties, both general and specific, that contribute to the possibility that the predictions, forecasts, projections and other forward-looking statements will not occur, which may cause actual performance and results in future periods to differ materially from any estimates or projections of future performance or results expressed or implied by such forward-looking statements. These assumptions, risks and uncertainties include, among other things, the state of the economy in general and capital markets in particular, investor interest in the business and future prospects of the Company.
The forward-looking statements contained in this news release are made as of the date of this news release. Except as required by law, the Company disclaims any intention and assumes no obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by applicable securities law. Additionally, the Company undertakes no obligation to comment on the expectations of, or statements made, by third parties in respect of the matters discussed above.
News Out! The NeuroCatch Platform is a 6-Minute Brain Function Assessment System Licensed by Health Canada as a Class II Medical Device
VANCOUVER, British Columbia, July 22, 2021 (GLOBE NEWSWIRE) -- KetamineOne Capital Limited (“Ketamine One” or the “Company”) (NEO: MEDI) (OTC: KONEF) (Frankfurt: MY0), a company focused on consolidating medical clinics and becoming a North American leader in mental health treatments, is pleased to highlight the continued success of the Health Canada-approved NeuroCatch Platform (“NeuroCatch”) in use at its Integrated Rehab and Performance Ltd. (“IRP”) clinic in Victoria, BC. IRP has been an early adopter of NeuroCatch’s advanced brain-scanning technology to better understand brain health and neurocognitive function in patients since September of 2020. NeuroCatch continues to differentiate IRP from other rehabilitation clinics, along with its unique focus on patients from the Canadian Armed Forces, the Royal Canadian Mounted Police and various first responder organizations.
NeuroCatch is expected to remain a key part of IRP’s service offering as Ketamine One expands its network to new veteran-centric markets across Canada. Unique service offerings such as NeuroCatch help Ketamine One’s clinicians create more tailored treatment plans for patients, which can increase their effectiveness over time. Platforms like NeuroCatch are also significant as Ketamine One embarks on embracing digital therapeutics as a core element of its competitive strategy. Psychedelics-focused research, a growing network of medical clinics, a broad suite of patient treatment options and leading technologies including digital therapeutics are all being brought together to create a unique mental health platform under Ketamine One.
NeuroCatch:
In 2019, Health Canada approved the NeuroCatch Platform a class II medical device developed by HealthTech Connex Inc. that conducts a rapid 6-minute scan to measure and report on cognitive brain function. It is an easy-to-use, objective, rapid neuro-physiological brain function assessment system, that provides healthcare practitioners with objective measurements of specific brain functions: auditory sensation; basic attention and cognitive processing. Researchers and clinicians use this technology to gain insight into a range of common neurological conditions, including concussion and brain injury; dementia and neurological disease; post-traumatic stress disorder and mental health; and brain performance and human optimization.
Aside from its relationship with IRP, NeuroCatch is currently also collaborating or partnered with a long list of third parties including but not limited to Alberta Children’s Hospital, CAA Hockey, Canadian Space Agency, Equinox Integrative Wellness, Helius Medical Technologies, Kids Brain Health Network, Mayo Clinic, Toronto Rehabilitation Institute, University Health Network, University of Alberta, University of Calgary, University of Toronto, University of Victoria and Weill Cornell Medicine.
Nice to see $1.20s printing bit the $KONEF volume is still under half of its 10-day average volume...let's see if it picks up in Power Hour!
$KONEF Ketamine One Announces Adam Deffett as Interim CEO
https://finance.yahoo.com/news/ketamine-one-announces-adam-deffett-110000763.html
Agreed, the $KONEF 10-day average volume is 2000...already 364 within the first 70 minutes.
$KONEF News June 19, 2021
Ketamine One Engages Various Providers of Investor Relations and Media Services
https://finance.yahoo.com/news/ketamine-one-engages-various-providers-220000842.html
$KONEF Ketamine One Announces Adam Deffett as Interim CEO
The Company Has Launched a Search Process Subsequent to Former CEO and Director Robert Meister Stepping Down From His Roles
VANCOUVER, British Columbia, July 07, 2021 (GLOBE NEWSWIRE) -- KetamineOne Capital Limited (“Ketamine One” or the “Company”) (NEO: MEDI) (OTC: KONEF) (Frankfurt: MY0), a company focused on consolidating medical clinics and becoming a North American leader in mental health treatments, is pleased to announce that its Board of Directors (the “Board”) has appointed Adam Deffett as the Company’s Interim Chief Executive Officer (“CEO”) effective July 7, 2021. Mr. Deffett will continue to perform his duties as VP Capital Markets while holding the title of Interim CEO. Ketamine One’s former CEO, Robert Meister, has stepped down and also resigned from the Board to facilitate the Company’s pursuit of its new strategy subsequent to its previously announced name change. Ketamine One has launched on a search process to identify appropriate candidates and ultimately hire a permanent CEO to lead the Company, which it expects to complete in the coming months.
“I would like to thank Robert for stewarding the transition of the Company from an investment issuer under the name of Myconic Capital Corp. to a company dedicated to mental healthcare and the rebrand to Ketamine One,” said Adam Deffett, Interim CEO of Ketamine One. “I greatly appreciate the opportunity to lead Ketamine One during this exciting time as we execute on our vision of becoming a leader in mental health and wellness across North America. We are fortunate to have a leadership team with great depth, decades of operating experience and detailed knowledge of our businesses. Our team is working hard to establish Ketamine One as the preeminent mental health platform for patients, by aggregating existing medical clinics and establishing new locations, while supporting KGK Science as a leading clinical research organization and implementing leading technologies throughout the organization wherever possible,” added Mr. Deffett.
https://investorshub.advfn.com/secure/post_new.aspx?board_id=39822
KETAMINE ONE (OTC: $KONEF | NEO: $MEDI) is rapidly scaling its business to become a big player in the North American psychedelic-assisted therapy sector. Their business model incorporates a growing roster of clinics, telemedicine, contract research and digital therapeutics including novel wearable devices.
As legalization rolls out across North America, the psychedelic-assisted therapy sector is exploding with growth and ketamine clinics have arguably become the most profitable vertical in the space.
https://tradealert.microcapbull.com/ketamineonemedi
$KONEF News July 07, 2021
Ketamine One Announces Adam Deffett as Interim CEO
https://finance.yahoo.com/news/ketamine-one-announces-adam-deffett-110000763.html
Followers
|
2
|
Posters
|
|
Posts (Today)
|
0
|
Posts (Total)
|
90
|
Created
|
07/19/21
|
Type
|
Free
|
Moderators |
Volume | |
Day Range: | |
Bid Price | |
Ask Price | |
Last Trade Time: |